# Comparative Safety, Tolerability, Pharmacokinetic Study of AVT02 (100MG/ML) and Humira (100MG/ML) in Healthy Volunteers

> **NCT03579823** · PHASE1 · COMPLETED · sponsor: **Alvotech Swiss AG** · enrollment: 24 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Adalimumab 100 MG/ML [Humira]
- **DRUG:** AVT02 100MG/ML

## Key facts

- **NCT ID:** NCT03579823
- **Lead sponsor:** Alvotech Swiss AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-21
- **Primary completion:** 2018-08-24
- **Final completion:** 2018-08-24
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2019-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03579823

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03579823, "Comparative Safety, Tolerability, Pharmacokinetic Study of AVT02 (100MG/ML) and Humira (100MG/ML) in Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03579823. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*